Stay updated on Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Sign up to get notified when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.

Latest updates to the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page
- Check6 days agoChange DetectedThe page has been updated to reflect the final analysis of the Phase III REACH3 Study on Ruxolitinib, with a new publication date and revision number.SummaryDifference0.3%
- Check13 days agoChange DetectedThe webpage has been updated to include new facility names and locations, as well as additional drug information, particularly regarding Ruxolitinib and other treatments. Some previously listed locations and drug information have been removed.SummaryDifference12%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page has been updated to reflect new dates and a revision number, indicating a version change from v2.16.11 to v2.16.12.SummaryDifference0.5%
- Check34 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check41 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.4%
- Check49 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, indicating a potential improvement or update in the content or functionality.SummaryDifference0.1%
Stay in the know with updates to Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.